Company Commits DKK 15 Billion to Share Buyback
Novo Nordisk confirmed on March 23, 2026, that it is proceeding with its previously announced share repurchase program. The plan, initiated on February 4, 2026, authorizes the company to buy back up to DKK 15 billion of its own shares over a 12-month period. This capital return strategy is a conventional tool used to increase earnings per share (EPS) by reducing the number of outstanding shares and to signal to the market that management believes the stock is undervalued. The execution of the buyback provides a significant layer of price support at a critical time for the company.
Alzheimer's Drug Fails Key Trials on March 19
The buyback's continuation comes just days after Novo Nordisk announced a major clinical setback. On March 19, the company presented full data showing its oral semaglutide—the active ingredient in its blockbuster drugs Ozempic and Wegovy—failed to demonstrate any clinical benefit for patients with early Alzheimer's disease. The results from the two large-scale studies, EVOKE and EVOKE+, were a significant disappointment for the neurodegenerative field, which had high hopes for the GLP-1 drug class. Consequently, Novo Nordisk announced the complete termination of the program, erasing a potential future growth driver for its most important compound.
Generic Rivals Emerge With 80% Price Cuts in India
Compounding the clinical news, Novo Nordisk is facing a new commercial threat in India, a critical growth market. The company's patent on semaglutide has expired, opening the door for a wave of generic competition. Local manufacturers, including Sun Pharmaceutical and Dr. Reddy's Laboratories, have launched versions at discounts of up to 80% compared to Novo's branded price. For example, Sun Pharma's generic is priced around 3,400 rupees per month, sharply undercutting Novo Nordisk's price of 8,800 to 10,000 rupees. In response, Novo has reduced its own prices by 37% and is launching second-brand versions of its drugs through local partners to defend its market share.
Edgen Stock·Mar 23 2026, 12:41
